## Zsuzsanna Kürti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1759290/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Does Hospitalization Predict the Disease Course in Ulcerative Colitis? Prevalence and Predictors of Hospitalization and Re- Hospitalization in Ulcerative Colitis in a Population-based Inception Cohort (2000-2012). Journal of Gastrointestinal and Liver Diseases, 2020, 24, 287-292.	0.9	14
2	Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 467-472.	0.9	15
3	Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes. World Journal of Gastroenterology, 2020, 26, 759-769.	3.3	8
4	The Burden of Anemia Remains Significant over Time in Patients with Inflammatory Bowel Diseases at a Tertiary Referral Center. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 555-559.	0.9	4
5	Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade. Clinical Gastroenterology and Hepatology, 2019, 17, 2506-2513.e2.	4.4	24
6	High Adherence to Surveillance Guidelines in Inflammatory Bowel Disease Patients Results in Low Colorectal Cancer and Dysplasia Rates, While Rates of Dysplasia are Low Before the Suggested Onset of Surveillance. Journal of Crohn's and Colitis, 2019, 13, 1343-1350.	1.3	13
7	Perceived Quality of Care is Associated with Disease Activity, Quality of Life, Work Productivity, and Gender, but not Disease Phenotype: A Prospective Study in a High-volume IBD Centre. Journal of Crohn's and Colitis, 2019, 13, 1138-1147.	1.3	15
8	Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. Quality of Life Research, 2019, 28, 141-152.	3.1	41
9	Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic. Digestive and Liver Disease, 2019, 51, 340-345.	0.9	12
10	Progress with infliximab biosimilars for inflammatory bowel disease. Expert Opinion on Biological Therapy, 2018, 18, 633-640.	3.1	12
11	Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies. Digestive and Liver Disease, 2018, 50, 37-41.	0.9	9
12	Therapeutic preferences and outcomes in newly diagnosed patients with Crohn's diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database. BMC Gastroenterology, 2018, 18, 23.	2.0	3
13	Optimizing Patient Management in Crohn's Disease in a Tertiary Referral Center: the Impact of Fast-Track MRI on Patient Management and Outcomes. Journal of Gastrointestinal and Liver Diseases, 2018, 27, 391-397.	0.9	3
14	Can we Predict Disease Course with Clinical Factors?. Current Drug Targets, 2018, 19, 791-797.	2.1	2
15	Epidemiology of inflammatory bowel diseases from west to east. Journal of Digestive Diseases, 2017, 18, 92-98.	1.5	66
16	Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases. BMC Gastroenterology, 2017, 17, 97.	2.0	17
17	Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database. Digestive and Liver Disease, 2016, 48, 1302-1307.	0.9	31
18	â€~Treat to Target' - Lessons Learnt. Digestive Diseases, 2016, 34, 147-152.	1.9	5

ZSUZSANNA KüRTI

#	Article	IF	CITATIONS
19	Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2016, 51, 848-854.	1.5	39
20	Adenomatous polyps in ulcerative colitis and colonic Crohn's disease: less frequent, but does this change surveillance strategy?. Endoscopy, 2016, 48, 210-212.	1.8	1
21	Optimal line of hepatotomy for left lateral living donor liver transplantation according to the anatomical variations of left hepatic duct system. Pediatric Transplantation, 2015, 19, 510-516.	1.0	6
22	Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort. Scandinavian Journal of Gastroenterology, 2015, 50, 306-311.	1.5	16
23	Burden ofClostridium difficileinfection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. World Journal of Gastroenterology, 2015, 21, 6728.	3.3	32
24	Prevalence and predictors of hospitalization in Crohn's disease in a prospective population-based inception cohort from 2000-2012. World Journal of Gastroenterology, 2015, 21, 7272-7280.	3.3	35
25	Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. European Journal of Health Economics, 2014, 15, 121-128.	2.8	41
26	Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres. Digestive and Liver Disease, 2014, 46, 985-990.	0.9	28